External Collaborative Research Grants: Non-Small Cell Lung Cancer
Boehringer Ingelheim have been transforming lives in healthcare since 1885. Our approximately 54,500 employees in 130 markets create value through innovation by infusing long-term, sustainable thinking into our Human Pharma and Animal Health units.
-
Real-world data: The natural history, development and progression of the disease, molecular testing and pathological subtyping, diagnostic/treatment landscape, and efficacy/safety outcomes
-
Monotherapy or combination therapy (including novel treatment combinations) in NSCLC with a documented HER2 aberration: TKD and non-TKD mutation positive OR overexpression OR gene amplification OR gene rearrangement involving HER2
The preliminary budget for ECRs should reflect fair market value for all costs and cannot include direct
salary support for the principal investigator. Budgets for ECRs will be further negotiated pending
finalization of the collaborative protocol.
Although the research interests listed within the therapeutic areas are of focus to Boehringer Ingelheim,
other research interests may be considered.
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.